Peter Tai-Ching Ho - Oct 24, 2022 Form 4 Insider Report for Aravive, Inc. (ARAV)

Role: Director
Signature: /s/ Abel Svitavsky, Attorney-in-fact
Stock symbol: ARAV
Transactions as of: Oct 24, 2022
Transactions value $: $49,999
Form type: 4
Date filed: 10/26/2022, 05:00 PM
Previous filing: Sep 26, 2022

This filing has been restated, see here for the amended filing

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ARAV	Common stock	Award	$50K	+54.4K	+5435.3%	$0.92	55.4K	Oct 24, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ARAV	Series A Warrants (right to buy)	Award		+27.2K			27.2K	Oct 24, 2022	Common stock	27.2K	$0.79	Direct	F1, F2, F3
transaction	ARAV	Series B Warrants (right to buy)	Award		+27.2K			27.2K	Oct 24, 2022	Common stock	27.2K	$0.79	Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On October 24, 2022, Aravive, Inc. (the "Company") agreed to issue approximately $41.5 million of securities including shares of its common stock and warrants (the "Warrants") to purchase shares of common stock in a private placement transaction (the "Private Placement") to certain investors, including the reporting person. The combined purchase price of each share of common stock and accompanying Warrants is $0.9199.
F2	The Series A Warrants are exercisable at any time after the Authorized Share Increase (as defined below) and will expire on the date that is the later of (i) fifteen (15) months after the date of the Authorized Share Increase, or (ii) one (1) month after public announcement by or on behalf of the Company of the publication of top line data from the Company's Phase 3 trial of batiraxcept in platinum-resistant ovarian cancer.
F3	In connection with the Private Placement, the Company has agreed to convene a special meeting of its stockholders or to seek written consent of the stockholders no later than 120 days following the closing of the Private Placement to seek approval of an increase in the number of the Company's authorized shares of common stock pursuant to an amendment to the Company's Certificate of Incorporation (such increase, the "Authorized Share Increase") to allow for full sufficient authorized and unissued shares of common stock for the full exercise of all of the Warrants and the shares of common stock issuable upon exercise thereof.
F4	The Series B Warrants are exercisable at any time after the Authorized Share Increase and will expire thirty (30) months after the Authorized Share Increase.